The suspension of WHO’s hydroxychloroquine clinical trial was to be taken up by an expert committee last week, but the discussions were eventually ‘deferred’.
More than a hundred scientists have raised questions about the dataset used in the study published by The Lancet, which led to WHO halting all trials of HCQ.
ICMR DG Balram Bhargava’s statement comes amid rising concern on hydroxychloroquine increasing mortality rate when used as a treatment in Covid-19 patients.
A Lancet study Friday said HCQ raises chances of death and irregular heart rhythm. On the same day, ICMR advised expansion of HCQ usage as prevention drug.
Trump, who at 73 is in an age group at which contracting Covid-19 can be especially dangerous, began HCQ treatments in consultation with White House physicians.
While the commission didn’t mention provisions under which IndiGo's market domination would be examined, Competition Act 2002 prohibits abuse of dominant position by any enterprise.
It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS